Скачать или смотреть Tacrolimus launched as the fourth drug to be tested in MND-SMART

Researchers have begun trialling a new drug for people affected by motor neuron disease (MND), also commonly referred to as ALS.

Tacrolimus is a medication already approved for use in a range of conditions to suppress the body’s immune system, including to prevent rejection after organ transplants. Promising laboratory research in human cells has shown it may be able to slow the progression of MND.

The drug is being tested in MND-SMART (Motor Neuron Disease – Systematic Multi-arm Adaptive Randomised Trial), an innovative clinical trial platform, led by the Euan MacDonald Centre at the University of Edinburgh, and a flagship project of the UK Dementia Research Institute.

MND-SMART is enabling hundreds of people living with MND to take part in tests of potential treatments. Almost 1000 people have been enrolled at 22 sites across the UK since the trial launched in 2020.

For more information visit https://mnd-smart.org/